The Cancer Letter

The leading source for information on the issues that shape oncology since 1973

Funding Opportunities

LUNGevity issues RFA for 2018 Career Development Award in translational research in lung cancer

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

LUNGevity Foundation has issued a Request for Application for translational research in lung cancer for the 2018 Career Development Award.

LUNGevity Career Development Awards support future research leaders who will keep the field of lung cancer research vibrant with new ideas.

The award, for translational early detection or therapeutics projects, including immuno-oncology projects, is open to junior faculty members who are within the first five years of their first faculty appointment.

Successful applicants may receive up to $100,000 per year for a possible period of three years and will participate as ex officio members of LUNGevity’s Scientific Advisory Board for the duration of the award. LUNGevity will grant only one Career Development Award per institution.

The Requests for Applications will be posted as of Jan. 16, 2018, on the LUNGevity website and on the proposalCENTRAL website.

For more information, contact Margery Jacobson at mjacobson@LUNGevity.org or 312-407-6109.

Table of Contents

YOU MAY BE INTERESTED IN

Podcast

“There is no safe harbor:” FY26 funding bill collapses after ICE shooting of Alex Pretti

In last week’s issue of The Cancer Letter, Jacquelyn Cobb, associate editor, wrote a story about the then-promising legislative package that was passed by the U.S. House of Representatives Jan. 22. At the time, the package was expected to pass in the Senate, provide funding for the federal government through fiscal year 2026, and prevent a government shutdown that looms Jan. 30. 
Clinical

Premarin’s 84-year hold on the market ends as FDA approves a generic version
Trade secret protections helped the hormone drug resist generic entry and outlast safety controversies—including link to cancer

A story is told that after first obtaining approval for marketing Premarin in 1942, Wyeth Laboratories didn’t lock up the secret recipe for making the hormonal drug in a company safe, to be guarded by patent lawyers.
By Claire Marie Porter
Capitol Hill

Spending bill passed by the House gives NIH $415M raise, NCI gets $128M
Legislation caps proportion of NIH grants to receive multiyear funding; indirect costs remain untouched

The U.S. House of Representatives Jan. 22 passed a three-bill minibus package that is expected to be the grand finale of the drama of the fiscal year 2026 appropriations process. The package, which funds the HHS as well as the departments of Defense, Transportation, Housing and Urban Development, Labor, and Education, gives NIH and NCI modest raises over FY25, and nullifies several  aggressive cuts the White House had proposed for NIH.
By Jacquelyn Cobb
Guest Editorial

Blood Cancer United: A new name at the right moment

This past summer, the organization I lead, formerly known as The Leukemia & Lymphoma Society, announced our new name: Blood Cancer United. It reflects our ongoing commitment to the entire blood cancer community—patients, families, caregivers, researchers, healthcare professionals, and partners—and our work to advance progress for those impacted by all types of blood cancer. 
By E. Anders Kolb
Table of Contents

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login

Site license subscribers:
Log in with your IP | Register a sponsored account